Depreciation of Taysha Gene Therapies, Inc. from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Taysha Gene Therapies, Inc. quarterly and annual Depreciation in USD history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • Taysha Gene Therapies, Inc. Depreciation for the quarter ending 30 Sep 2025 was $200,000, a 33% decline year-over-year.
  • Taysha Gene Therapies, Inc. Depreciation for the twelve months ending 30 Sep 2025 was $1,103,000, a 13% decline year-over-year.
  • Taysha Gene Therapies, Inc. annual Depreciation for 2024 was $1,245,000, a 9.2% decline from 2023.
  • Taysha Gene Therapies, Inc. annual Depreciation for 2023 was $1,371,000, a 17% increase from 2022.
  • Taysha Gene Therapies, Inc. annual Depreciation for 2022 was $1,172,000, a 138% increase from 2021.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Taysha Gene Therapies, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,103,000 $200,000 -$100,000 -33% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $1,203,000 $300,000 $0 0% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $1,203,000 $283,000 -$42,000 -13% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $1,245,000 $320,000 -$20,000 -5.9% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
Q3 2024 $1,265,000 $300,000 $0 0% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $1,265,000 $300,000 -$100,000 -25% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $1,365,000 $325,000 -$6,000 -1.8% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $1,371,000 $340,000 +$28,000 +9% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q3 2023 $1,343,000 $300,000 $0 0% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $1,343,000 $400,000 +$100,000 +33% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $1,243,000 $331,000 +$71,000 +27% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $1,172,000 $312,000 +$137,000 +78% 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
Q3 2022 $1,035,000 $300,000 +$100,000 +50% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $935,000 $300,000 +$215,000 +253% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $720,000 $260,000 +$228,000 +712% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $492,000 $175,000 01 Oct 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
Q3 2021 $200,000 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $85,000 +$85,000 01 Apr 2021 30 Jun 2021 10-Q 16 Aug 2021 2021 Q2
Q1 2021 $32,000 +$32,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q2 2020 $0 $0 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $0 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $0 21 Sep 2019 31 Dec 2019 10-K 03 Mar 2021 2020 FY
Q3 2019 $0 21 Sep 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3

Taysha Gene Therapies, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,245,000 -$126,000 -9.2% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
2023 $1,371,000 +$199,000 +17% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
2022 $1,172,000 +$680,000 +138% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
2021 $492,000 +$483,000 +5367% 01 Jan 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
2020 $9,000 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.